BridgeBio Pharma is a biopharmaceutical company to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. Co.'s pipeline includes: Acoramidis (Eidos), which is an oral small molecule Transthyretin (TTR) stabilizer for the treatment of TTR amyloidosis; Low-dose Infigratinib, which is an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of achondroplasia; BBP-418, which is a small molecule substrate replacement therapy for the treatment of Limb Girdle Muscular Dystrophy Type 2I; and BBP-812, which is an adeno-associated virus gene therapy for the treatment of Canavan Disease. The BBIO YTD return is shown above.
The YTD Return on the BBIO YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BBIO YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BBIO YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|